Cargando…
A Japanese, Multicenter, Open-label, Phase 3 Study to Investigate the Safety and Efficacy of Gadobutrol for Contrast-enhanced MR Imaging of the Central Nervous System
PURPOSE: Gadobutrol 1.0 M is macrocyclic gadolinium-based contrast agent for magnetic resonance imaging (MRI). This multicenter, open-label, phase 3 study aimed to investigate the efficacy and safety of gadobutrol-enhanced versus unenhanced MRI in the visualization and diagnosis of central nervous s...
Autores principales: | TANAKA, Akio, MASUMOTO, Tomohiko, YAMADA, Haruyasu, KURAUCHI, Masayo, BREUER, Josy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society for Magnetic Resonance in Medicine
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600060/ https://www.ncbi.nlm.nih.gov/pubmed/26687097 http://dx.doi.org/10.2463/mrms.mp.2015-0083 |
Ejemplares similares
-
Inter-individual Comparison of Gadobutrol and Gadoteridol Tissue Time-intensity Profiles for Dynamic Susceptibility Contrast Perfusion MR Imaging
por: Yamada, Masahiro, et al.
Publicado: (2018) -
Safety and Efficacy of Gadobutrol for Contrast-enhanced Magnetic Resonance Imaging of the Central Nervous System: Results from a Multicenter, Double-blind, Randomized, Comparator Study
por: Gutierrez, Juan E, et al.
Publicado: (2015) -
Correction to “Safety and Efficacy of Gadobutrol for Contrast-enhanced Magnetic Resonance Imaging of the Central Nervous System: Results from a Multicenter, Double-blind, Randomized, Comparator Study”
por: Gutierrez, Juan E, et al.
Publicado: (2015) -
Safety of Gadobutrol: Results From 42 Clinical Phase II to IV Studies and Postmarketing Surveillance After 29 Million Applications
por: Endrikat, Jan, et al.
Publicado: (2016) -
Gadobutrol: A Review in Contrast-Enhanced MRI and MRA
por: Scott, Lesley J.
Publicado: (2018)